The activation of transcription factor NF-κB (nuclear factor-κB) plays a central role in the induction of many inflammatory response genes. This process is characterized by either oscillations or stable induction of NF-κB nuclear binding. Changes in dynamics of binding result in the expression of distinct subsets of genes leading to different physiological outcomes. We examined NF-κB DNA binding activity in LPS-stimulated IC-21 cells by EMSA and NTFA assay and interpreted the results using a kinetic model of NF-κB activation. Both assays detected damped oscillatory behavior of NF-κB with differences in sensitivity and reproducibility. 3,4-Dichloropropionaniline (DCPA) was used to modulate the oscillatory behavior of NF-κB following LPS stimulation. DCPA is known to inhibit production of two of NF-κB inducible cytokines, IL-6 and TNF-α, by reducing but not completely abrogating NF-κB-induced transcription. DCPA treatment resulted in a potentiation of early LPS-induced NF-κB activation. Results from the NTFA assay, with a higher signal-to-noise ratio than EMSA, combined with in silico modeling revealed changes in NF-κB dynamics which have never been previously reported. These results highlight the importance of cell type and stimuli specificity in transcription factor activity assessment. In addition, assay selection has important implications for network inference and drug discovery.
Introduction
thus they are visualised by discrete bands of radioactivity in the upper part of an acrylamide gel image (19, 20) . This technique is labor intensive and requires radioactivity.
NTFA technique combines the principle of EMSA where protein:DNA interaction is observed in enzyme-linked immunosorbent assay format (21) (22) (23) . Active NF-κB is captured as it binds to its non-radioactive DNA consensus sequence that has been immobilized on a streptavidin-coated plate. The transcription factor which formed complexes with DNA is then probed with specific primary antibody (anti-p65) followed by HRP-conjugated secondary antibody and substrate detection. This method allows sampling a larger number of tests in a shorter period of time and does not require radioactive labeling.
The present study explores the initial phase of nuclear NF-κB oscillatory behavior induced in LPS-stimulated macrophages by the means of two independent methods commonly used for quantifying the binding activity of transcription factors. Immunosuppressant DCPA is used to modulate NF-κB activity and incorporated in the dynamic model to demonstrate the changes in transcription factor activation. Methods Cell culture, stimulation and DCPA treatment. The murine peritoneal macrophage cell line, IC-21, was cultured in 5% CO 2 at 37°C to 80% confluency in complete RPMI (cRPMI) (BioWhittaker, Walkerville, MD). cRPMI consists of RPMI 1640 supplemented with 10% fetal bovine serum (Hyclone, Logan, UT), L-glutamine (2 mM), penicillin (100 U/ml), streptomycin (100 μg/ml), 2-mercaptoethanol (5 x 10 -5 M), and Hepes buffer (10 mM) (all obtained from Sigma-Aldrich, St. Louis, MO). IC-21 cells were treated with 99% pure DCPA (ChemService, Inc., West Chester, PA) and simultaneously stimulated with 1 μg/ml LPS phenol extracted (Sigma-Aldrich) for various times.
The human T cell line, Jurkat clone E6-1, was cultured in 5% CO 2 at 37°C in cRPMI. Jurkat cells were treated with 99% pure DCPA and simultaneously stimulated with plate-bound anti-CD3 and anti-CD28. Anti-CD3 coated plates were prepared by adding 10 mg/ml mouse anti-human CD3 (Ancell Corp, Bayport, MN) to the wells and incubating for 90 minutes at 37°C followed by storage overnight at 4°C. Prior to the addition of the cells, the unbound anti-CD3 was aspirated out of the wells and the wells were washed three times with sterile phosphate buffered saline. Jurkat cells were diluted to 1 x 10 6 cells/ml in cRPMI and DCPA was added to the cells. Next, the Jurkat cells were added to the anti-CD3 coated wells and 2 mg/ml of anti-CD28 (Ancell Corp) was added to each well. Nuclear extracts were isolated after cells were incubated for the appropriate times.
Appropriate concentrations of DCPA were dissolved in 100% ethanol (Mallinckrodt Baker, Inc., Paris, KY) and added to cells at concentrations ranging from 0 to 150 μM. The final ethanol concentration added to all cultures was 0.1%; control cultures received equal concentrations of ethanol. Nuclear Extracts. IC-21 cells were plated at a concentration of 8 x 10 5 cells in 5 ml of cRPMI in 60 mm dish and incubated overnight at 37°C 5% CO 2 . IC-21 cells were then treated with either 0.1% ethanol or DCPA at concentrations of 25 μM, 100 μM, 150 μM, then stimulated with 1 μg/ml LPS. IC-21 cells were washed with 2.5 ml of ice-cold Dulbecco's phosphate buffered saline (DPBS) (BioWhittaker) and lysed by adding 200 μl of a buffer (lysis buffer) consisting of 10 mM HEPES pH 7.9, 10 mM KCl, 0.1 mM ethylenediamineteraacetic acid (EDTA), 0.1 mM ethylene glycol-bis(2-aminoethyl ether) N, N, N', N'-tetraacetic acid (EGTA), 1 mM phenyl methyl sulfonyl fluoride (PMSF), 1 mM dithiothreitol (DTT), and 1 μg/ml of the protease inhibitors leupeptin, antipain, chymostatin and pepstatin A (Sigma-Aldrich). IC-21 cells were scraped off the dishes and lysates were transferred to a microcentrifuge tubes. For the Jurkat cells, following anti-CD3/anti-CD28 stimulation, the cells were harvested from the wells by vigorous pipetting followed centrifugation to pellet the cells. The cells was washed with 2.5 ml of ice-cold DPBS and lysed by adding 200 μl of the lysis buffer. Once in lysis buffer all cells were incubated on ice for 15 min. Next, 50 μl of 10% NP-40 was added, samples were vortexed for 30 sec and the lysates were pelleted by centrifugation for 30 sec at 14000 rpm at 4°C. The supernatants (cytoplasmic extracts) were collected and saved at -20°C. Pellets were resuspended in 30 μl of 20 mM HEPES buffer containing 400 mM NaCl, 1mM EDTA, 1 mM EGTA, 1mM PMSF, 1 mM DTT and 1 μg/ml of the protease inhibitors (see above), vortexed and incubated for 15 min on ice. The lysates were pelleted by centrifugation at 14000 rpm for 5 min at the same conditions and the supernatants containing the nuclear fraction stored at -70°C. A total protein concentration for nuclear extracts was determined with Coomassie Plus Protein Assay Reagent, as described by manufacturer (Pierce, Rockford, IL). Electrophoretic mobility shift assay (EMSA). NF-κB consensus oligonucleotides (sc-2505; Santa Cruz Biotechnology, Santa Cruz, CA) were labeled with γ-32 P-ATP (PerkinElmer, Boston, MA) using Ready-To-Go TM T4 polynucleotide kinase kit (Amersham Pharmacia Biotech Inc., Piscataway, NJ). Nuclear extracts, 5μg per sample, were incubated with 50,000 cpm of labeled probe and 1 μg/ml dI:dC for 30 min at room temperature in 1x binding buffer (5x stock: 250 mM NaCl, 50 mM Tris-Cl, 50% (v/v) glycerol, 5 mM DTT, 2.5 mM EDTA, adjusted to pH 7.6, stored at-20°C) to allow formation of band shift complexes. Next, complexes were resolved from free probe in 5% polyacrylamide gels (1× TGE, 5% glycerol, 0.075% ammonium persulfate, 0.1% TEMED). Samples were electrophoresed at 125 V for 4 h, dried on Whatman 3MM paper, and placed on PhosphoImage Screens for analysis with ImageQuant TL Software (Amersham Pharmacia Biotech Inc.). The EMSA experimental results are reported as the ratio of the intensity measured for a particular condition (i.e. time > 0) relative to the intensity of nuclear NF-κB prior to treatment (i.e. time = 0). Transcription factor assay (NTFA). Nuclear extracts, 5 μg per sample, were analyzed by a Chemicon Non-Radioactive Transcription Factor Assay to determine NF-κB p65 DNA binding activity, as described by manufacturer (Chemicon Int., Temecula, CA). Briefly, nuclear extracts were incubated for 2 h with biotinylated NF-κB consensus DNA sequences in a transcription assay buffer containing sonicated salmon sperm DNA to allow the formation of protein/DNA complexes. Next, NF-κB protein in the nuclear extracts bound to biotinylated consensus sequences was immobilized to the streptavidin-coated plate, and any unbound material was washed away. NF-κB protein was detected with a specific rabbit anti-p65 antibody, followed by incubation with anti-rabbit HRP-conjugated antibody detected by TMB/E substrate. Absorbance of the samples was measured with a μQuant Universal Microplate Spectrophotometer (Bio-Tek Instruments, Winooski, VT). The NTFA experimental results are reported as the ratio of the absorbance measured for a particular condition (i.e. time > 0) relative to the absorbance prior to treatment (i.e. time = 0). NF-κB Model Development. The development of a mathematical model for NF-κB activation was shaped by two primary considerations: 1) the design of experiments that minimize potential sources of biological variability and 2) the ability to uniquely determine parameter values from replicate measurements. To quantify the effect of DCPA on LPS-stimulated NF-κB activation, we focused on the first 45 minutes following LPS-stimulation (see Discussion). While more detailed mathematical models for NF-κB have been proposed in the literature (e.g., (5)), the experimental objectives of this study required developing a new mathematical model that has identifiable parameters (see Appendix). This new model implicitly represents a series of biological events that occur within the timeframe of experimental interest. The stimulation of macrophages by LPS results in the activation of the TLR4 pathway (24) . The transduction of signals via TLR4 results in the activation of a series of intermediate signaling proteins and ultimately in the activation of IKK. The activation of IKK leads to the liberation of NF-κB from protein complexes with IκB inhibitor proteins. Active NF-κB translocates to the nucleus where it initiates the transcription of various genes, including the IκB proteins. Newly transcribed and translated IκB proteins reenter the nucleus and deactivate NF-κB. Shown schematically in Figure 1 , the initial dynamics of NF-κB activation following LPS stimulation is represented by the following three chemical kinetic equations:
where cN, aN, iN, and DCPA represent the concentrations of inactive NF-κB in the cytosol, active NF-κB in the nucleus, IκBα, and DCPA, respectively. TLR4 is a boolean variable that is equal to 1 when the cells are stimulated by LPS. As the IC-21 macrophages were continually exposed to LPS, TLR4 is equal to 1 for all of the experiments studied. The dynamic change in NF-κB in the cytosol is represented by equation 1, where the impact of IKK on liberating NF-κB and transport to the nucleus is represented by a single parameter k1. We postulate that DCPA modulates the activation of NF-κB with the strength parameter α. A negative value for α signifies that DCPA inhibits the activation of NF-κB while a positive value potentiates. The change in active NF-κB in the nucleus is represented by equation 2, where the second term represents the inactivation of nuclear NF-κB by IκBα. The dynamic transcription, translation, reimport to the nucleus of the NF-κB inhibitor protein, IκBα, in response to active NF-κB, and degradation is represented by equation 3. Additional terms could be added to these three equations to account for recycling of NF-κB-IκBα complex to the cytosol. However, inclusion of these additional terms did not improve the fitness of the model within the timeframe of experimental interest (data not shown). The initial normalized concentrations of aN and iN were set equal to 1 and 0, respectively. The estimates for the initial concentration of cN and parameters k1, α, k3, and k4 were determined using these three ordinary differential equations and experimental measurement of active NF-κB in the nucleus. The half-maximal inhibition constant, K DCPA , was assumed to be 5 μM based on the study by Xie et al. (14) . The rate constant for the deactivation of active NF-κB in the nucleus, k2, was assumed to be equal to 0.015 conc -1 min -1 . These three ordinary differential equations were evaluated within MatLab V7.1 (MathWorks, Natwick, MA). Summed-squared error between experimentally measured and simulated values for active NF-κB in the nucleus was used to determine goodness-of-fit. Optimal values for the parameters were selected using a genetic algorithm and are detailed in the Table 1 . Parameter values were determined from the combined analysis of all DCPA conditions using a single assay platform (i.e., there are two sets of parameters: θ EMSA and θ NTFA ).
Confidence intervals for the parameters were determined using Bootstrap re-sampling. Bootstrap Re-sampling -Confidence Interval Estimation. The bootstrap re-sampling is an effective method for the estimation of confidence intervals of model parameters (25) . Let's assume that the experimental measurement of a dynamic system can be described by the following equation:
where y exp (t i , A j ) is the measured value at time t i using assay A j and θ j is the vector of model parameters for assay j that are constant with respect to time. A mechanistic model of the dynamic system provides an estimate of the expected biological response, y mod (t i , θ j ), at time t i , given the parameter vector θ j . The measurement error for a particular assay, or residual, is represented by ε j (t i ) and can be obtained at each time point, t i . The population of ε j (t i ) determined from the data set is a representative sample of the variability in observing this phenomena experimentally using a particular assay. Analysis of the variance ensures that there are no systematic errors in the residual population. Experimentally, replication is used to establish significance of an observation. Bootstrap re-sampling is a computational approach that creates synthetic replicates drawn from the population of residuals. The residuals are first normalized based on the appropriate error model of the experimental assay. Normalization is performed to ensure that the residuals are independent of the dependent variables. Error models for each of the assays (NTFA and EMSA) were based upon an analysis of the residuals. The statistical significance for the difference in the variance of residuals was estimated using the ratio of variances as a test statistic. The test statistic was compared against the F-distribution, where the degrees of freedom were determined from the size of the two groups. A p-value less than 0.05 was considered statistically significant. Synthetic sets of experimental replicates were created using the following steps. First, optimal values for k1, k3, α, and the initial value for cN were determined based upon the DCPA doseescalation experiments using either NTFA or EMSA. Second, expected values (y mod (t i , θ j )) were calculated using equations 1-3 (the NF-κB model) and the set of optimal parameters, using either θ EMSA or θ NTFA , for every measured experimental condition (y exp (t i , A j )) to yield the residuals, ε j (t i ).
The residuals were normalized based upon the error model that corresponds to the particular assay. Finally, a large number (N boot = 3000) of synthetic data sets (i.e. bootstrapped data sets) that replicate the original experimental protocol were created by sampling, with replacement, from the population of residuals. These re-sampled residuals are then combined with the expected values (y mod (t i , θ j )) to give new synthetic data sets. A new optimal set of parameter values were determined for the NF-κB model that capture the synthetic DCPA dose-escalation experiments. Each one of the bootstrap data sets yields a novel set of values for k1, k3, α, and the initial value of cN. This collection of optimal values provides an estimate of the 95% confidence intervals for k1, k3, α, and cN(t = 0), shown in the Table 1 . The reported significance corresponds to the probability that the strength parameter α is positive. The bootstrap approach provides a good estimate of the confidence intervals compared against classical statistical techniques, given a sufficiently large bootstrap sample (i.e., N boot ≥1000) and data sample (i.e., N data ≥ 30) (26) . An alternative bootstrapping approach is to re-sample directly from the population of biological replicates, instead of the population of residuals. Bootstrap re-sampling of the biological replicates would require greater than 30 replicates performed at each experimental condition. In this study, each residual value was considered an independent observation. Bootstrap re-sampling of the residuals was justified as the residuals appeared to be randomly distributed around the expected values within the biological replicates for each DCPA treatment conditions (data not shown).
Results
We first wanted to characterize the dynamics of NF-κB activation in macrophage cell line. As shown in Figure 2 , sustained LPS stimulation of a mouse peritoneal macrophage cell line, IC-21, resulted in damped oscillations in NF-κB DNA binding activity. Over a period of six hours, the dynamic activation of NF-κB was quantified using an electromobility shift assay (EMSA) at the indicated time points (Figure 2a) . IC-21 macrophages were treated with either ethanol (control) or 100 μM DCPA and stimulated with LPS to induce active NF-κB DNA binding. Both treatments demonstrated similar damped oscillations graphically represented in Figure 2b (EtOH -solid line, open circles, 100 μM DCPA -dashed line, plus sign). These damped oscillations observed in macrophages are in variance with the findings of Covert et al. (27) which demonstrate sustained NF-κB activation following LPS stimulation in mouse embryonic fibroblasts. While the EMSA measurements shown in Figure 2 are representative of the dynamic response in IC-21 macrophages to LPS, significant variability was observed between replicates following the initial peak in NF-κB activation (data not shown). Moreover, observed variability in amplitude of response and frequency of response inhibited the ability to quantify the pharmacological effect of a particular mediator on the dynamics of NF-κB. Based on these findings, we focused subsequent efforts on quantifying the dynamics of NF-κB activation within the first 45 minutes following LPS stimulation.
Next, both EMSA and NTFA were used to replicate measurements of active NF-κB in the nucleus at multiple time points during initial peak of DNA binding activity (0-45 min) in response to LPS stimulation. Figure 3a demonstrates multiple replicates of this process using EMSA, for comparison, Figure 3b represents the data obtain from NTFA. Both methods demonstrated the initial peak of NF-κB activation which reached maximum at 20 min caused by rapid degradation of IκBα inhibitor and resulted in maximum DNA binding. Subsequent diminishing of NF-κB binding activity, triggered by a re-synthesis of IκBα, is graphically displayed as a decline of the curve. A mathematical model, shown schematically in Figure 1 , incorporating these biochemical steps was created to capture this dynamic behavior. Parameter values that correspond to a particular assay are shown in Table 1 . The EMSA measurements obtained from LPS-induced macrophage cell line are compared against the mathematicallysimulated EMSA response in Figure 3a represented by solid (ethanol) and dashed (150 μM DCPA) lines. For comparison, data from NTFA is compared against mathematically-simulated NF-κB activation dynamics in Figure 3b . The overall kinetics of the underlying biological mechanism observed using the NTFA and EMSA assays are in agreement. The results of comparison between the two assays revealed that NTFA exhibits greater sensitivity and reproducibility in measuring active NF-κB relative to the EMSA as shown by the differences in dynamic ranges observed during the control experiments.
To manipulate the dynamics of NF-κB oscillatory behavior, a known immunosuppressant, DCPA, was introduced into the experimental system. IC-21 macrophages were treated with three different doses of DCPA: 25, 100, and 150 μM DCPA and simultaneously stimulated with LPS. In order to quantify the effect of DCPA on dynamics of binding activity, we focused on the initial peak of NF-κB activation following LPS stimulation. Both assays were used to characterize alterations in NF-κB binding activity by DCPA in response to LPS stimulation, and experimental results from EMSA and NTFA are show in Figures 3a and 3b , respectively. All doses of DCPA are graphically represented by a separate sign (25 μM -"○", 100 μM -"+"; 150 μM -"×"). The effect of DCPA on the dynamic activation of NF-κB was represented in the mathematical model by modulating the activation rate of NF-κB in the cytosol, k1. The pharmacologic effect of DCPA on the initial activation of NF-κB was quantified by the strength parameter α. Using the EMSA parameter values shown in Table 1 , the simulated NF-κB response to LPS following treatment with 150 μM DCPA was compared against the EMSA results in Figure 3a . Similarly, the simulated NTFA measurements following DCPA treatment were compared against the NTFA results in Figure 3b . Overall, the simulated responses for both NTFA and EMSA showed agreement with the experimentally measured values. In comparison, the simulated NTFA results showed greater discrimination between macrophages treated with DCPA and controls compared to the EMSA results. These differences were a reflection of the values of α estimated using NTFA versus EMSA. The results from both assays suggest that DCPA potentiates the activation of NF-κB at the early time points (0-45 min). Quantitatively, the NTFA results suggest that DCPA increases the activation rate of NF-κB by 48.0% (α = 0.480). In contrast, the EMSA results suggest that DCPA increases the activation rate by 11.9% (α = 0.119).
One of the most important aspects of data analysis is the determination of confidence intervals for model parameters that represent the data. A bootstrap resampling approach applied to the residuals (ε j (t i )) between the predicted (y mod (t i , θ j )) and measured (y exp (t i )) values was used to estimate the confidence intervals of the model parameters. Prior to applying the bootstrap algorithm, we analyzed the population of residuals for underlying structure. The residuals are assumed to have a Gaussian distribution with a zero mean (i.e.
, is a function of time, the model parameters, and a parameter vector that is unique to the variance of assay j, λ j . The underlying structure in the variance of the residuals is sometimes referred to as the error model. Separate error models were created for the EMSA and NTFA measurements. In this study, we assume that the error model is a linear function of the predicted value:
The parameter, λ 1,j , quantifies the variance that is proportional to the underlying signal that is being measured for assay j. The λ 2,j parameter quantifies the contribution of a random noise distribution to the error model for assay j. 
where Λ1 . The variances of the two groups for each assay are labeled in Figure 4 . The variance compared between the high and low NTFA groups was not statistically significant while the difference between the EMSA groups was significant (p<0.05). These results suggest that λ 2 is equal to zero for the NTFA error model and that the residuals are proportional only to the underlying signal (y mod ). In contrast, the variance in the EMSA measurements is proportional to the underlying signal and contains contributions from random noise. Given this analysis of the residuals for the NTFA and EMSA measurements, we constructed a bootstrap sample population using the following error models: The bootstrapped sample populations were used to provide estimates of the confidence intervals associated with the model parameters. The 95% confidence intervals for the model parameters are shown in the Table 1 . We are particularly interested in the confidence intervals associated with the strength parameter α. Based upon bootstrapping of the EMSA residuals, the 95% confidence interval for the strength parameter α spans the range -0.296 to 0.913 (p < 0.2). In contrast, the 95% confidence interval for the strength parameter α based on the NTFA residuals spans 0.021 to 1.53 (p < 0.02). The other estimated parameters (k1, k3, and cN) exhibited wider confidence intervals from the EMSA results compared to the NFTA results (e.g., O(10 1.6 ) for EMSA k3 versus O(10 0.8 ) for NTFA k3). Differences in the size of the confidence intervals indicate the differences in signal-to-noise ratios for these two assays.
To test the predictive power of the mathematical model, we also studied the influence of DCPA on NF-κB activation in a human T cell line, Jurkat clone E6-1 ( Figure 5 ). Jurkat cells were treated with either ethanol (squares) or 100 μM DCPA (+) and co-cultured with platebound anti-CD3 and anti-CD28 to activate NF-κB. The extent of active NF-κB DNA binding was measured using the NTFA. Activation of NF-κB in Jurkat cells was delayed compared to LPS-stimulated IC-21 macrophages. Due to the time-delay associated with the activation of NF-κB, the start of the simulation occurs 24 minutes after the Jurkat cells were exposed to anti-CD3/CD28. As the pathways leading to NF-κB activation following anti-CD3/CD28 stimulation (29) are different from LPS-induced activation (30), the ethanol control experiment (squares) was used to adjust the parameters associated with the initial concentration of inactive NF-κB in the cytosol (cN = 19) and the NF-kB activation rate constant (k1 = 0.015 min -1 ). All other parameters remained as specified in Table 1 . The predicted response in NF-κB activation following exposure to 100 μM DCPA (dotted line) is shown compared against the ethanol control (solid line).
Discussion
The combined experimental and simulation results using IC-21 cells, a mouse macrophage cell line, suggest that DCPA potentiates the early activation of NF-κB by 48.0%. In contrast, the EMSA results suggest that DCPA increases the activation rate by 11.9% (α = 0.119). The potentiation of NF-κB activation by DCPA was also confirmed using the NTFA in a human T cell line, Jurkat clone E6-1. These results seem counter-intuitive as we have previously reported that 66 μM DCPA resulted in an 80% reduction in IL-6 mRNA and a 50% reduction in TNF-α mRNA following stimulation with 10 μg/ml LPS (14) . This suppression in mRNA resulted in an inhibition of IL-6 production by 60% and TNF-α production by 50%. However, the stabilities of IL-6 and TNF-α mRNA were not affected by DCPA suggesting that DCPA modulates cytokine production specifically at the pre-transcriptional level as inhibition of the IκB proteins would change the dynamics of NF-κB.
In particular, the dynamic re-synthesis of the IκB inhibitor proteins following the initial activation induces oscillations in NF-κB (5). Conceptually, potentiating the activation of NF-κB by DCPA would cause an increase in the re-synthesis of IκB proteins. This proportional increase in IκB proteins would cause a more rapid reduction in active NF-κB, thus undershooting the concentration of active NF-κB in the nucleus compared to the control experiment. In Figure 3 , this undershoot was apparent at 40 minutes, where the nuclear NF-κB in DCPA-exposed cells was lower than the ethanol control. If, on the other hand, DCPA inhibited the re-synthesis of IκB proteins, the level of inducible NF-κB would increase following the initial rise (31) and gene expression would also increase. Such a concomitant increase in gene expression is inconsistent with prior studies (14) . Further evidence supports our hypothesis that DCPA modulates the activation of NF-κB at the pre-translational level, as similar affects on NF-κB activation were observed in LPS-stimulated mouse IC-21 macrophages and in human Jurkat T cells stimulated through the T cell receptor (compare Figure 3b with Figure 5 ). LPS activates NF-κB in IC-21 macrophages via the MyD88 pathway associated with TLR4 (30) . In contrast, NF-κB activation via stimulating the T cell receptor in Jurkat cells requires the recruitment of multiple signaling proteins to the central zone of the supramolecular activation cluster (c-SMAC) leading to protein kinase C (PKC)-controlled activation of NF-κB (29) . These two different signaling pathways converge at the polyubiquitin ligase, tumor necrosis factor receptor-associated factor 6 (TRAF6) (32, 33) . TRAF6 in turn activates IKK, which facilitates the degradation of the IκB inhibitory proteins. Collectively, these observations suggest that DCPA differentially regulates NF-κB-response genes via the IκB-NF-κB signaling module through a yet undefined pre-translational mechanism.
NF-κB regulates the inducible expression of a wide range of immune and inflammatory response genes (34) . As a result, NF-κB is one of the most studied molecules in the area of signal transduction. Due to the complex nature of biological system, the study of NF-κB is important for two reasons. First, the objective of biomedical research is to infer biochemical mechanisms that underpin biological response to stimuli. Second, biomedical research aims to develop strategies that modulate aberrant biochemical mechanisms to revert a pathogenic state. In both cases, biological assays provide avenues for observing cellular response following biochemical interrogation.
One of the most important aspects in the design of a biological assay is selecting a physiologically relevant context. We first observed damped oscillations in active NF-κB in macrophages following LPS stimulation. This observation is in contrast to other published studies examining the dynamic activation of NF-κB following LPS stimulation. In particular, Werner et al. observed in fibroblasts that the initial activation of NF-κB by 0.1 μg/ml LPS was not rapid but dependent on autocrine feedback via the TNF-α pathway (35) . Covert et al. observed that 0.5 μg/ml LPS induced stable NF-κB activation through a combination of MyD88-dependent and MyD88-independent pathways (27) . In Figure 6 , we compare our results to the results of Werner et al. (35) and Covert et al. (27) . The initial rates of NF-κB activation are similar in both previous studies using mouse embryonic fibroblasts. We observed a much higher initial rate of activation using 1.0 μg/ml LPS. This higher activation rate may be attributed to the increased expression of CD14 in macrophages compared to fibroblasts and/or increased stimulant. Cellular response to LPS is mediated by the TLR4 pathway (24) . CD14, an accessory cell surface protein, interacts with TLR4 to increase the sensitivity to LPS a thousand-fold (36) and facilitates the robust response to LPS. Moreover, NF-κB activation following TCR stimulation in Jurkat cells, as highlighted in Figure 5b , exhibits different dynamics than through the TLR4 pathway in IC-21 macrophages. Variations in the initial rate of activation of NF-κB reflect inherent differences in the efficacy of similar signaling pathways in different cell types that exist prior to stimulation. Thus, the cellular context plays an important role in determining the contribution of a particular signaling pathway on the dynamic behavior of NF-κB activation.
Chemical manipulation of NF-κB binding activity with immunosuppressant DCPA resulted in the earlier activation of the initial peak observed during first 45 minutes after LPS stimulation. This earlier activation might result in altered frequency of the oscillations which, in turn, will change the transcriptional regulation of some genes. Changes in number, period and amplitude of oscillations were observed by Nelson at al. (37) in HeLa cell line continuously stimulated with TNF-α. Furthermore, the transcription of NF-κB target genes was dependent on persistence of oscillations. Nelson et al. (37) also suggest that changes in oscillations could have functional consequences on NF-κB signaling in response to different stimuli. Therefore, inhibition of NF-κB-inducible cytokines, TNF-α and IL-6, observed in DCPA treated cells at the later time points (12 and 24 h after sustained LPS stimulation) may be a result of the early potentiation of NF-κB activation caused by a shift in oscillatory behavior.
An additional consideration in the design of a biological assay is how to observe a cellular response. Observed variability in measured data is due to technical variation (e.g. error in measurement) or biological variation (e.g. cellular heterogeneity, asynchrony, or stochasticity). Implicitly, design of the experimental protocol is intended to limit the contributions of biological variation by selecting cellular systems that exhibit favorable characteristics. A survey of the prior literature suggests experimental conditions that can reduce natural sources of biological variation. In the study by Lipniacki et al. (38) , stochastic simulations revealed that the dynamics of the initial peak is independent of the number of NF-κB molecules. Similarly, Nelson et al. demonstrated that the dynamics of the initial peak were similar among cells expressing fluorescently-labeled RelA (37) . Collectively, these studies and our own data suggest that, by focusing on the first 45 minutes following LPS stimulation, natural sources of biological variability can be minimized.
In contrast, the contribution of technical variation has received little attention. Moreover, the experimental tools of molecular biology have been criticized due to their qualitative nature (39, 40) . Over the years, biochemical assays have been developed with improved sensitivity (23) . Yet, as we have shown herein, technical variation can be attributed to multiple sources. Improved sensitivity alone is an insufficient criterion to improve the information context of an assay. If the technical variation is associated solely with the magnitude of the signal, there will be no difference in extracting meaningful information regarding cellular response using either assay. However, when an assay, such as the EMSA assay discussed here, exhibits a higher contribution of random noise, pharmacologically significant modulation of cellular response and insight into underlying biological mechanisms can be masked. Thus, an assay, such as NTFA, that provides a greater signal-to-noise ratio affords a clearer window into fundamental cellular behavior. The importance of developing biological assays that exhibit improved signal-to-noise ratios is highlighted by our study of the potentiation of NF-κB activation by DCPA.
While much effort has focused on identifying the dynamic phenomena associated with the activation of NF-κB, we focused our efforts on understanding how this dynamic phenomena can be modulated for therapeutic aims. Following our investigations into the impact of DCPA on the dynamic modulation of NF-κB activation within a mouse peritoneal macrophage cell line and a human T cell line, we come to the following three conclusions. First, the dynamic behavior of NF-κB in response to stimuli is dependent on cell type and developmental stage. Second, DCPA potentiates early activation of NF-κB yet suppresses inflammatory gene expression. Extraction of this counter-intuitive behavior could only be achieved through the use of a mechanistic model that encoded the relevant biochemical events. Furthermore, ascribing significance to parameter values derived from a mechanistic model must include parameter identifiability considerations and the analysis of multiple biological replicates. Finally, nonradioactive transcription factor assays provide superior signal-to-noise ratios over electromobility shift assays for observing cellular NF-κB response.
Appendix Parameter Identification.
An important aspect of sensitivity analysis is to identify model parameters that can be uniquely determined from the available data. A priori identifiability is one approach to select identifiable parameters given unlimited information about the modeled system (41, 42) . This assessment of parameter identifiability is intimately linked to the sensitivity of the model results to changes in parameter values. Local sensitivity analysis is defined as the relative change in model variables (y j ) in response to a perturbation of the model parameters (k i ) around a local optimum (43) . The resulting sensitivity function is defined as, where the partial derivative values are scaled by the parameter value and the maximum value of the model variable during the simulation. In practice, the sensitivity function is approximated by obtaining the sensitivity measure S ij at a set of discrete time points, t k , and experimental conditions, [Cn] n . In addition, measurements of only a subset the model variables may be obtained experimentally. A reduced sensitivity matrix (M) is then constructed using a subset of the sensitivity measures
A set of correlation coefficients between model parameters is calculated from M. Parameters that are locally identifiable have correlations with all other parameters between -1 and +1. Parameters that are not locally identifiable, termed a priori unidentifiable, have correlations of exactly +1 or -1 with at least one other parameter.
The identifiability of the model parameters and initial concentration of NF-κB in cytosol (cN (t = 0)) were calculated using the NF-κB model described in Equations 1 -3. A combined sensitivity matrix was constructed from sensitivity values obtained from simulations with 0 and 100 μM DCPA over a period of 50 minutes following LPS-stimulation. This combined sensitivity matrix was reduced by assuming that the concentration of active NF-κB in the nucleus ([aN] ) was the only experimentally observable variable in the model. We are particularly interested in the confidence intervals associated with the strength parameter α. The correlation coefficients listed in Table A1 demonstrate that estimates of the strength parameter α are unique if K DCPA is specified to be 5 μM, as determined previously (14) . Table 1 . List of variables and parameters for NF-κB activation model. Optimal value for initial conditions and parameters were determined using a genetic algorithm. Separate values were determined from dose-escalation measurements obtained using EMSA or NTFA assays. Nonparametric bootstrapping using residual errors provided estimates of confidence intervals. These two signaling pathways act through TRAF6 to activate the IκB-NF-κB signaling module. (b) Nuclear NF-κB was assayed by NTFA at the indicated times after stimulation with plate-bound anti-CD3 and anti-CD28 and treatment with 0μM (□) and 100 μM (+) DCPA. Two parameters (k1 and cN) of the mathematical model were calibrated to the ethanol control results, providing a prediction of the 100 μM DCPA results. The simulated time courses of active NF-κB in the absence and pretreated with 100 μM DCPA are shown as the solid curves and dashed curves, respectively. Each experiment was performed six times. Figure 6 . The dynamic activation of NF-κB in macrophages compared against prior studies using fibroblasts. Nuclear NF-κB was assayed by EMSA at the indicated times after persistent stimulation with 1 μg/ml LPS in macrophages (□, this study, n = 8, values reported as average ± 95% confidence interval), 0. 
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